1.Early screening and diagnosis of prostate cancer based on the innovative care for chronic conditions framework.
Han-Jing ZHU ; Liang DONG ; Bin ZHAO ; Feng ZHANG ; Rong LI ; Cheng-Ye ZHU ; Jia MAO ; Zhen-Ying YANG ; Yin-Jie ZHU ; Wei XUE
National Journal of Andrology 2025;31(3):229-233
OBJECTIVE:
To construct an integrated management model for early screening and diagnosis of PCa based on the Innovative Care for Chronic Conditions Framework (ICCC) and the 1+1 contract-based tiered diagnosis and treatment system (TDTS) in China.
METHODS:
Based on the 1+1 contract-based TDTS platform, we conducted PCa screening for the male residents aged 60 years and above during health check-ups in Pujin Community Health Center from January 1, 2023 to December 31, 2023. For those with abnormal total prostate-specific antigen (tPSA) ≥ 4 μg/L, we promptly referred them to higher-level hospitals for further diagnosis and treatment via the two-way referral green channel platform and information sharing service using the 1+1 contract model. We further analyzed the relevant data on screening and diagnosis.
RESULTS:
A total of 4 080 males aged 71.39±5.059 years received PCa screening from January to December 2023. PSA screening was performed in 43.96% of the male residents, revealing 654 cases of PSA abnormality, with a PSA positivity rate of 16.03%, which was higher than that found in the previous large-scale PCa screenings in other regions of China. Among the males with PSA abnormality, 292 (44.65%) expressed their willingness for medical referral, while the others did not seek further medical attention for reasons of being asymptomatic, low awareness of the disease, no accompany for medical visits, and concerns about further costs of diagnosis and treatment. Prostate biopsy was recommended to 154 cases after further examinations, which was accepted by 92 (59.74%). Fifty-eight cases were diagnosed with Pa, and thedetection rate reached 63.04%.
CONCLUSION
The integrated management model for PSA examination-based early screening and diagnosis of PCa using the 1+1 contract-based TDTS platform is plays a significant role in enhancing people's awareness and knowledge of PCa and improving the early detection rate of the malignancy.
Humans
;
Male
;
Prostatic Neoplasms/diagnosis*
;
Early Detection of Cancer
;
Prostate-Specific Antigen/blood*
;
Aged
;
China
;
Mass Screening
;
Middle Aged
;
Chronic Disease
2.Clinical prediction model for patients with early-onset prostate cancer without surgical treatment: Based on the SEER Database.
Han-Dong LIU ; Han-Yu JIA ; Jing WANG ; Li-Ping ZHANG
National Journal of Andrology 2025;31(5):412-420
OBJECTIVE:
The aim of this study is to investigate the risk factors of prognosis in patients with early-onset prostate cancer treated without surgery. A nomogram will be constructed and validated to predict overall survival (OS) of patients with early-onset prostate cancer treated without surgery.
METHODS:
The clinical data was obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database on prostate cancer patients aged 18-55 years who were treated without surgery between 2010 and 2015. The clinical data set was divided into training set and validation set according to 7∶3 ratio, including age, race, marital status, Gleason score, prostate specific antigen (PSA) and other 8 factors. And significant variables were screened by univariate Cox regression analysis. Multivariate Cox regression analysis was used to identify the influence factors. Stepwise regression method was used to select the most influential factors on the total OS, and R software was used to build a nomogram model. The accuracy and prediction ability of the model were verified by drawing receiver operating characteristic (ROC) and Calibration Plot. The clinical benefit of the model was evaluated by decision curve analysis (DCA).
RESULTS:
A total of 8 212 patients who met the criteria were randomly assigned to the training set (n=5 752) or validation set (n=2 460), with no statistical difference between the two groups (all P>0.05). Six factors were identified through univariate and multivariate Cox regression analysis including marital status, N stage, M stage, radiotherapy, PSA and Gleason score, which were most closely associated with the OS of prostate cancer patients, and a column graph model was constructed based on these factors. The Consistency index (C-index) of the model in the training set and the verification set were 0.802 and 0.794, respectively. And the apparent diffusion coefficient (AUC) was 0.851, 0.855 and 0.855 for training sets 1, 3 and 5 years, and 0.694, 0.860 and 0.832 for verification sets 1, 3 and 5 years. The calibration chart showed a good agreement between the predicted and actual values of the model. In the analysis of decision curve, the model showed good clinical application value.
CONCLUSION
The prediction model based on marital status, radiotherapy, M stage, N stage, PSA and Gleason score for early-onset prostate cancer patients without surgical treatment has certain reference value which is expected to become an effective tool for clinicians to treat in future prospective studies on large and multi-center samples.
Humans
;
Male
;
Prostatic Neoplasms/diagnosis*
;
Middle Aged
;
Nomograms
;
SEER Program
;
Prognosis
;
Adult
;
Prostate-Specific Antigen
;
Risk Factors
;
Proportional Hazards Models
;
Neoplasm Grading
;
ROC Curve
3.Joint detection of serum NLR, PSA and MMP26 in differentiating prostate cancer from benign prostatic hyperplasia.
Yi-Jin WANG ; Qiang LI ; Guang-Bo FU
National Journal of Andrology 2025;31(5):421-425
OBJECTIVE:
To explore the application value of joint detection of serum neutrophil-to-lymphocyte ratio (NLR), prostate-specific antigen (PSA) and MMP26 in differentiating prostate cancer (PCa) from benign prostatic hyperplasia (BPH).
METHODS:
A total of 61 PCa patients (PCa group) and 63 BPH patients (BPH group) who were treated in The Affiliated Huaian Hospital of Xuzhou Medical University from May 2022 to May 2024 were retrospectively included. The relevant clinical data of all subjects were collected with the serum NLR, PSA and MMP26 levels being detected. Multivariate logistic regression analysis was used to analyze the influencing factors in differentiating PCa from BPH. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of serum NLR, PSA and MMP26 in differentiating PCa from BPH.
RESULTS:
The levels of TC and LDL-C in the PCa group were higher than those in the BPH group. And the level of HDL-C in the PCa group was lower than that in the BPH group (P<0.05). The serum levels of NLR, PSA and MMP26 in the PCa group were higher than those in the BPH group (P<0.05). The results of multivariate logistic regression analysis showed that NLR, PSA and MMP26 were risk factors for the diagnosis of PCa in patients (P<0.05). The ROC results showed that the area under the curve (AUC) of NLR, PSA MMP26 and joint diagnosis in the identification of PCa was 0.804, 0.800, 0.809 and 0.905, respectively. The comparison results of AUC showed that the joint diagnosis was superior to the single diagnosis (Z=2.262, 2.177, 2.002, P<0.05).
CONCLUSION
The joint detection of serum NLR, PSA and MMP26 has significant application value in the differentiation of PCa and BPH, which is expected to become an effective tool for early screening and diagnosis of PCa.
Humans
;
Male
;
Prostatic Hyperplasia/blood*
;
Prostate-Specific Antigen/blood*
;
Diagnosis, Differential
;
Prostatic Neoplasms/blood*
;
Retrospective Studies
;
Neutrophils
;
Lymphocytes
;
ROC Curve
;
Aged
;
Middle Aged
4.Diagnostic value of ultrasonic shear wave elastography for clinically significant prostate cancer.
Fang-Rui YANG ; Yong-Hao JI ; Li-Tao RUAN ; Jian-Xue LIU ; Yao-Ren ZHANG ; Xiao ZHANG ; Qin-Yun WAN ; Si-Fan REN
National Journal of Andrology 2025;31(6):505-511
OBJECTIVE:
To explore the diagnostic value of shear wave elastography (SWE) for clinically significant prostate cancer (csPCa).
METHODS:
We retrospectively analyzed the clinical data of 359 cases with suspected prostate cancer (PCa) in Baoji Central Hospital from June 2017 to July 2023. All the patients underwent the following examinations in the order of serum prostate-specific antigen (PSA) testing, transrectal ultrasonography (TRUS), measurement of the stiffness of the entire prostate gland by SWE, and TRUS-guided prostate puncture biopsy. The stiffness of the entire prostate gland was defined as the average of Young's modulus at both sides of the base, middle, and apex of the prostate, including the maximum Young's modulus (Emax), mean Young's modulus (Emean), and minimum Young's modulus (Emin). We analyzed the correlation of the parameters of the stiffness of the entire prostate gland with the pathological results, focusing on their diagnostic performance for csPCa.
RESULTS:
Of the 359 cases, 189 were diagnosed by pathological puncture biopsy as BPH, 26 as non-csPCa, and 144 as csPCa. The PSA level, Emax, Emean and Emin were significantly higher in the csPCa than those in the BPH and non-csPCa groups (all P < 0.01), but showed no statistically significant difference between the BPH and non-csPCa groups (all P > 0.05). The area under the receiver operating characteristic curve (AUC), optimal cut-off value, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of Emax in the diagnosis of csPCa were 0.852, 143.92 kPa, 72.22%, 84.65%, 75.91%, 81.98% and 79.67%; those of Emean were 0.868, 82.42 kPa, 67.36%, 91.16%, 83.62%, 80.66% and 81.62%; and those of Emin were 0.682, 32.73 kPa, 47.22%, 89.30%, 73.91%, 71.54% and 72.14%, respectively. In the non-csPCa group, Emax, Emean and Emin were found below the optimal cut-off value in 73.08% (19/26), 92.31% (24/26) and 88.46% (23/26), respectively.
CONCLUSION
The stiffness of the entire prostate gland measured by SWE contributes to the diagnosis of csPCa, reduces unnecessary detection of non-csPCa, and provides some reference for its active surveillance.
Humans
;
Male
;
Prostatic Neoplasms/diagnosis*
;
Elasticity Imaging Techniques
;
Retrospective Studies
;
Prostate/pathology*
;
Prostate-Specific Antigen/blood*
;
Aged
;
Middle Aged
5.Research progress on screening prostate cancer in the PSA"gray zone"and PI-RADS 3 lesions.
National Journal of Andrology 2025;31(6):547-551
Prostate cancer is a common tumor of the male genitourinary system, with its incidence continuously increasing. Early accurate diagnosis is crucial for treatment and prognosis. PSA and MRI are important methods for screening and diagnosis of prostate cancer. However, there is still controversy over whether patients with PSA levels between 4-10 μg/L and PI-RADS score of 3 need to undergo prostate biopsy. Radiomics technology provides a new approach for the early and accurate diagnosis of prostate cancer by mining and analyzing medical image information in a high throughput, which helps to reduce unnecessary biopsies. This article reviews the research progress of MRI radiomics in the screening of prostate cancer in the "gray zone" of PSA and PI-RADS score of 3, aiming to improve diagnostic accuracy and provide references for future research in the field of radiomics.
Humans
;
Male
;
Prostatic Neoplasms/diagnosis*
;
Prostate-Specific Antigen/blood*
;
Magnetic Resonance Imaging
;
Early Detection of Cancer
;
Biopsy
;
Prostate/pathology*
6.Role of the prostate health index and its derivatives in the early screening of patients with PI-RADS score 3.
Tong-Qing ZHANG ; Qiang FU ; Hao LIU ; Ying-Tao LIU ; Ke-Qin ZHANG
National Journal of Andrology 2025;31(7):612-618
OBJECTIVE:
To explore the role of prostate health index (PHI) and its derivatives for early screening in patients with PI-RADS score 3 and prostate-specific antigen (PSA) levels of 4-20 μg/L.
METHODS:
Clinical data of 203 patients with a score of 3 on the PI-RADS v2.1 scoring system who underwent ultrasound-guided transperineal prostate aspiration biopsy from April 2021 to April 2024 from Provincial Hospital of Shandong First Medical University, Qilu Hospital of Shandong University and Weifang People's Hospital were collected. Patients who met the inclusion criteria were divided into prostate cancer (PCa) group (62 cases) and benign prostatic hyperplasia (BPH) group (141 cases). Serum total prostate-specific antigen (tPSA), serum free prostate-specific antigen (fPSA), and PSA isoform 2 (p2PSA) were routinely detected after admission. And prostate-specific antigen density (PSAD), prostate health index (PHI) and prostate health index density (PHID) were calculated with the basic personal information being collected. The efficacy of each parameter in early screening of patients with PI-RADS score of 3 and PSA level of 4-20 μg/L was assessed using ROC curve approach.
RESULTS:
There was no statistical difference in tPSA, fPSA and fPSA/tPSA between the two groups (P>0.05). There was a statistical difference in p2PSA, PSAD, PHI, PHID and age between the two groups (P<0.05). PHI (AUC=0.783 7, 95% CI: 0.711 3-0.856 1) and PHID (AUC=0.782 3, 95% CI: 0.708 3-0.856 4) showed a good predictive ability in the early screening of prostate cancer. In the clinically significant prostate cancer (csPCa) group, the ROC curve areas of PHI and PHID were 0.823 0 and 0.788 5, respectively, which showed better predictive efficacy of prediction of csPCa. The ROC curves of the combined diagnostic indexes were plotted on the basis of the independent ROC curves, and the area under the curve of PHI combined with age, p2PSA and PHID (AUC=0.843 6) was the largest and had the best predictive ability among all the combined diagnostic indexes.
CONCLUSION
In patients with PI-RADS score 3 and PSA level between 4 and 20 μg/L, PHI and its derivatives (PHI and PHID) provide a new way for early screening of prostate cancer compared with the traditional index tPSA, which has a high value of application in reducing the over-penetration.
Humans
;
Male
;
Prostatic Neoplasms/diagnosis*
;
Prostate-Specific Antigen/blood*
;
Prostatic Hyperplasia/diagnosis*
;
Prostate/pathology*
;
Early Detection of Cancer
;
ROC Curve
;
Middle Aged
;
Aged
7.Research progress on screening methods for early prostate cancer.
Mei-Hui ZHANG ; Hua CHENG ; Hao-Yong NING
National Journal of Andrology 2025;31(8):737-741
Prostate cancer is a common malignant tumor of the male urinary system. Early diagnosis is very important to improve the survival rate and quality of life of patients. In this paper, the screening methods for early prostate cancer will be systematically reviewed, covering serum prostate-specific antigen (PSA) related testing, non-PSA related testing, as well as emerging genetic and genetic testing technologies. The principle, advantages and limitations of each screening method will be briefly analyzed as well. In order to avoid excessive puncture biopsy, a basis for reasonable clinical screening strategy for prostate cancer will be introduced, so as to realize early detection, diagnosis and treatment of disease and improve the prognosis of patients.
Humans
;
Male
;
Prostatic Neoplasms/diagnosis*
;
Early Detection of Cancer/methods*
;
Prostate-Specific Antigen/blood*
8.Predictive efficacy of serum hepcidin, ferritin, and q-Dioxn MRI for upgrading, upstaging, and biochemical recurrence in prostate cancer patients: A comparative study.
Zhen TIAN ; Guang-Zheng LI ; Ren-Peng HUANG ; Si-Yu WANG ; Li-Chen JIN ; Yu-Xin LIN ; Yu-Hua HUANG
National Journal of Andrology 2025;31(9):800-806
OBJECTIVE:
The aim of this study is to explore the correlation among serum hepcidin, ferritin, and q-Dioxn MRI with upgrading, upstaging and biochemical recurrence in prostate cancer (PCa) patients.
METHODS:
A total of 103 PCa patients diagnosed by biopsy were selected for this study. All patients underwent q-Dixon MRI prior to biopsy for T2* value measurement. Then serum hepcidin and ferritin were measured before receiving radical prostatectomy. Pathological grading and staging were conducted both preoperatively and postoperatively. The correlations among hepcidin, ferritin, T2* values, and postoperative upgrading, upstaging, biochemical recurrence were subsequently analyzed.
RESULTS:
The hepcidin level of PCa patients was measured at (123.51 ± 23.03) ng/mL, while the ferritin level was recorded at (239.80 ± 79.59) ng/mL, and the T2* value was (41.07 ± 6.37) ms. A total of 49 and 36 cases were observed with upgrading and upstaging in postoperative pathology, respectively. The median follow-up duration was 28.0 months (6.0-38.0 months), during which biochemical recurrence was observed in 12 cases. For upgrading, hepcidin and ferritin demonstrated the predictive efficacy, with areas under the ROC curve of 0.777 and 0.642, respectively, whereas T2* values did not show sufficient predictive power. For upstaging, hepcidin, ferritin, and T2* exhibited predictive efficacy, with areas under the ROC curve of 0.806, 0.696, and 0.655, respectively. Multivariate Logistic regression analysis indicated that hepcidin served as an independent risk factor for both upgrading (OR 1.055, 95%CI 1.027-1.085, P<0.001) and upstaging (OR 1.094, 95%CI 1.040-1.152, P<0.001). Cox regression analysis showed that hepcidin (95%CI 1.000-1.052, P = 0.049) was a significant risk factor for predicting biochemical recurrence.
CONCLUSION
Hepcidin could serve as a predictor for pathological upgrading, upstaging and biochemical recurrence after radical prostatectomy, which provides a novel potential index for risk stratification and prognostic evaluation of PCa patients.
Humans
;
Male
;
Prostatic Neoplasms/diagnosis*
;
Hepcidins/blood*
;
Ferritins/blood*
;
Middle Aged
;
Magnetic Resonance Imaging/methods*
;
Aged
;
Neoplasm Recurrence, Local
;
Neoplasm Staging
9.Application of machine learning algorithms in predicting new onset hypertension: a study based on the China Health and Nutrition Survey.
Manhui ZHANG ; Xian XIA ; Qiqi WANG ; Yue PAN ; Guanyi ZHANG ; Zhigang WANG
Environmental Health and Preventive Medicine 2025;30():3-3
BACKGROUND:
Hypertension is a serious chronic disease that can significantly lead to various cardiovascular diseases, affecting vital organs such as the heart, brain, and kidneys. Our goal is to predict the risk of new onset hypertension using machine learning algorithms and identify the characteristics of patients with new onset hypertension.
METHODS:
We analyzed data from the 2011 China Health and Nutrition Survey cohort of individuals who were not hypertensive at baseline and had follow-up results available for prediction by 2015. We tested and evaluated the performance of four traditional machine learning algorithms commonly used in epidemiological studies: Logistic Regression, Support Vector Machine, XGBoost, LightGBM, and two deep learning algorithms: TabNet and AMFormer model. We modeled using 16 and 29 features, respectively. SHAP values were applied to select key features associated with new onset hypertension.
RESULTS:
A total of 4,982 participants were included in the analysis, of whom 1,017 developed hypertension during the 4-year follow-up. Among the 16-feature models, Logistic Regression had the highest AUC of 0.784(0.775∼0.806). In the 29-feature prediction models, AMFormer performed the best with an AUC of 0.802(0.795∼0.820), and also scored the highest in MCC (0.417, 95%CI: 0.400∼0.434) and F1 (0.503, 95%CI: 0.484∼0.505) metrics, demonstrating superior overall performance compared to the other models. Additionally, key features selected based on the AMFormer, such as age, province, waist circumference, urban or rural location, education level, employment status, weight, WHR, and BMI, played significant roles.
CONCLUSION
We used the AMFormer model for the first time in predicting new onset hypertension and achieved the best results among the six algorithms tested. Key features associated with new onset hypertension can be determined through this algorithm. The practice of machine learning algorithms can further enhance the predictive efficacy of diseases and identify risk factors for diseases.
Humans
;
China/epidemiology*
;
Hypertension/diagnosis*
;
Machine Learning
;
Male
;
Female
;
Middle Aged
;
Adult
;
Nutrition Surveys
;
Algorithms
;
Aged
;
Risk Factors
10.Validation of the Japanese version of MemScreen: a rapid screening tool for mild cognitive impairment.
Ai IKEDA ; Hadrien CHARVAT ; Takeshi TANIGAWA ; Nobuto SHIBATA ; Koutatsu MARUYAMA ; Kiyohide TOMOOKA ; Yukari ASAI ; Juna KAMIJIMA ; Qisheng LI ; Noemi ENDO ; Saori MIYAZAKI ; Archana SINGH-MANOUX ; Julien DUMURGIER
Environmental Health and Preventive Medicine 2025;30():96-96
This study was to examine the validity of the Japanese version of MemScreen (MemScreen-J), a touchscreen MCI screening test. 20 patients with MCI aged 65-90 years at the Juntendo Tokyo Koto Geriatric Medical Center were recruited as cases in December 2023. Non-cases were recruited from local residents in Toon City, Ehime Prefecture in February 2024 and 40 residents, without a medical history of MCI, aged 58-84 years were included in the present study. MemScreen-J test, a self-administered screening test in the form of a digital application, downloadable on a tablet, was administered to participants to assess their cognitive function. Defining the group at high risk of MCI based on a MemScreen-J test score of 28 or lower achieved the best Youden index in the study sample, with a sensitivity of 0.75 and a specificity of 0.98. MemScreen-J appeared to be a valid screening tool among persons at the prodromal stage of dementia, given reasonably high accuracy in detection of MCI. This innovative neuropsychological test could be the first step in a diagnostic approach to cognitive complaints in a community, identifying persons at the preclinical stage of dementia.
Humans
;
Cognitive Dysfunction/diagnosis*
;
Aged
;
Aged, 80 and over
;
Male
;
Female
;
Japan
;
Neuropsychological Tests
;
Middle Aged
;
Mass Screening/methods*
;
Sensitivity and Specificity
;
Reproducibility of Results
;
East Asian People

Result Analysis
Print
Save
E-mail